Thinking about cancer or dealing with cancer risk can be scary or overwhelming, but we believe that receiving information and resources is comforting, empowering, and lifesaving.
Two relatively new treatments are available for women with recurrent ovarian cancer that is caused by a mutation in BRCA1 or BRCA2.
Lynparza (also known as olaparib) is a PARP inhibitor drug approved by the FDA to treat ovarian, fallopian tube, and primary peritoneal cancer in women who carry a BRCA mutation, and who have received three or more previous lines of chemotherapy. Lynparza has also been approved in Europe, but for a different indication: it is used there as maintenance therapy for recurrent BRCA-related ovarian cancer in women who have a good response to platinum chemotherapy.
Rubraca (also known as rucaparib) is approved to treat women with advanced ovarian cancer who have had two or more prior treatment and who have inherited mutations in BRCA or whose tumors have BRCA mutations as detected by the FoundationFocus CDxBRCA companion diagnostic.
A new treatment is also available for maintenance therapy in women with recurrent ovarian cancer whose cancer responded to their last platinum therapy.
Zejula (also known as niraparib), a new PARP inhibitor, is approved for maintenance therapy for women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have had at least two prior chemotherapy treatments and are in complete or partial response to their last round of chemotherapy. Zejula is approved for maintenance therapy for all ovarian, fallopian tube or primary peritoneal cancer regardless of BRCA mutation status.
For more information on Lynparza, Rubraca, Zejula, and other PARP inhibitors in clinical trials, please visit our PARP inhibitor page.